Babraham Bioscience Technologies Ltd has announced the initiation of a new bioincubator building programme at the Babraham Research Campus, further expanding Babraham's capacity for supporting early-stage companies and biomedical innovation.

Research from the Babraham Institute has revealed for the first time that genes work together by huddling in clusters inside the nucleus - the information centre of a cell.

It may not be immediately apparent, but scientific environments are heavy users of energy. Research is not a 9 to 5 job; researchers are dedicated souls who burn the midnight oil – or electricity – and then some.

Proximagen Neuroscience says it plans to keep Cambridge Biotechnology at the Babraham Research Campus on completion of its acquisition of the drug discovery outfit from Swedish pharmaceutical, Biovitrum.

Biovitrum has found a buyer for its UK drug discovery subsidiary, Cambridge Biotechnology Ltd (CBT).

Babraham Institute spin-out, Crescendo Biologics has secured £4.5m in a seed funding round led by Paris-based venture capital firm, Sofinnova Partners.

It has been quite a year so far for Senexis Ltd, the Babraham-based private drug development company dedicated to unfolding the science of senescence to revolutionise the diagnosis and treatment of ageing-related diseases.

A Babraham-based company is on the verge of an exciting international breakthrough with a new diagnostic test for bladder cancer.

Life sciences knowledge transfer specialist, Babraham Bioscience Technologies (BBT) has appointed a new CEO following the sudden resignation of the previous holder of the post.

A discovery by scientists at the Babraham Institute in Cambridge could lead to innovative treatments to tackle abnormal thickening of the heart muscle.

Innova Biosciences has been awarded €455k (£407k) of a €3m European grant to develop a screening tool for early-stage cancer.

New bug busting technology from a Cambridge company could help NHS Trusts blitz MRSA in UK hospitals.

{mosimage}Scientists based at The Babraham Institute have begun to unpick the complex mechanisms that underpin the development of drug resistant cancers.